paroxetine has been researched along with 10-hydroxynortriptyline in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Andersson, K; Bertilsson, L; Härtter, S; Laine, K; Svensson, JO; Tybring, G; Widén, J | 1 |
| Derijks, HJ; Grootens, K; Jessurun, N; Mikes, O; Otten, LS; van Marum, RJ; van Puijenbroek, EP; Vermeulen Windsant, A | 1 |
| Derijks, HJ; Grootens, K; Jessurun, NT; Mikes, O; van Marum, RJ; van Puijenbroek, EP; Vermeulen Windsant, A | 1 |
1 trial(s) available for paroxetine and 10-hydroxynortriptyline
| Article | Year |
|---|---|
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Topics: Adult; Antidepressive Agents, Tricyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hypotension, Orthostatic; Male; Middle Aged; Mixed Function Oxygenases; Nortriptyline; Paroxetine; Phenotype; Tremor; Xerostomia | 2001 |
2 other study(ies) available for paroxetine and 10-hydroxynortriptyline
| Article | Year |
|---|---|
Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels - a review of routine practice.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Cytochrome P-450 CYP2D6 Inhibitors; Depression; Drug Interactions; Female; Humans; Middle Aged; Nortriptyline; Paroxetine | 2017 |
Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels-A prospective pharmacokinetic study.
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Humans; Nortriptyline; Paroxetine; Prospective Studies | 2021 |